Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program
October 15, 2015 at 04:20 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY) and Five Prime Therapeutics, Inc. (Nasdaq: FPRX) today announced that ...
